In summary, the Talazoparib Beyond BRCA trial is a prospective study that identifies the sensitivity of gPALB2 breast cancers to PARP inhibition and highlights the core role of PALB2 in BRCA1- and/or BRCA2-mediated HR DNA repair in human breast cancers. The gene discussed is BRCA1; the disease is breast carcinoma.